<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04810611</url>
  </required_header>
  <id_info>
    <org_study_id>CMBG453E12101</org_study_id>
    <nct_id>NCT04810611</nct_id>
  </id_info>
  <brief_title>Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS</brief_title>
  <official_title>A Phase Ib, Multicenter, Open-label Platform Study of Select Drug Combinations in Adult Patients With Lower Risk (Very Low, Low, or Intermediate Risk) Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety, tolerability and confirm the dose&#xD;
      for select single agents and combinations in patients with lower risk (very low, low, and&#xD;
      intermediate risk) MDS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2021</start_date>
  <completion_date type="Anticipated">November 16, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose interruption reduction</measure>
    <time_frame>30 Months</time_frame>
    <description>Dose tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of DLTs</measure>
    <time_frame>30 Months</time_frame>
    <description>Incidence of dose limiting toxicities (DLTs) during the first 2 cycle of treatment during the dose escalation/confirmation part</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose intensity</measure>
    <time_frame>30 Months</time_frame>
    <description>Dose tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AE and SAE indicence</measure>
    <time_frame>30 months</time_frame>
    <description>Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as per CTCAE v5.0, by treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single agents and combinations on transfusion dependent patients: Best Overall Response (BOR)</measure>
    <time_frame>30 Months</time_frame>
    <description>Evaluate change in transfusion burden and hematologic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single agents and combinations on transfusion dependent patients: Duration of Response (DOR)</measure>
    <time_frame>30 Months</time_frame>
    <description>Evaluate change in transfusion burden and hematologic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single agents and combinations on transfusion dependent patients: Progression free survival (PFS)</measure>
    <time_frame>30 Months</time_frame>
    <description>Evaluate change in transfusion burden and hematologic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single agents and combinations on transfusion dependent patients: Time to progression (TTP)</measure>
    <time_frame>30 Months</time_frame>
    <description>Evaluate change in transfusion burden and hematologic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single agents and combinations in patients who are transfusion independent: Best Overall Response (BOR)</measure>
    <time_frame>30 Months</time_frame>
    <description>Evaluate change in hematologic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single agents and combinations in patients who are transfusion independent: Duration of Response (DOR)</measure>
    <time_frame>30 Months</time_frame>
    <description>Evaluate change in hematologic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single agents and combinations in patients who are transfusion independent: Progression Free Survival (PFS)</measure>
    <time_frame>30 Months</time_frame>
    <description>Evaluate change in hematologic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single agents and combinations in patients who are transfusion independent: Time to Progression (TTP)</measure>
    <time_frame>30 Months</time_frame>
    <description>Evaluate change in hematologic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize pharmacokinetics for single agents and combinations: Cmax</measure>
    <time_frame>30 Months</time_frame>
    <description>Serum concentrations and derived PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize pharmacokinetics for single agents and combinations: Tmax</measure>
    <time_frame>30 Months</time_frame>
    <description>Serum concentrations and derived PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize pharmacokinetics for single agents and combinations: Ctrough</measure>
    <time_frame>30 Months</time_frame>
    <description>Serum concentrations and derived PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the prevalence of immunogenicity</measure>
    <time_frame>30 Months</time_frame>
    <description>Anti-drug antibody prevalence at baseline and on treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single agents and combinations on transfusion dependent patients: Overall Response Rate (ORR)</measure>
    <time_frame>30 Months</time_frame>
    <description>Evaluate change in transfusion burden and hematologic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single agents and combinations in patients who are transfusion independent: Overall Response Rate (ORR)</measure>
    <time_frame>30 Months</time_frame>
    <description>Evaluate change in hematologic parameters</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Arm 1: MBG453 single agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with MBG453 single agent Q4W to confirm safety and tolerability of RD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: NIS793 single agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with NIS793 single agent Q3W to establish RD in this indication and confirm safety and tolerability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: canakinumab single agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with single agent canakinumab Q4W to confirm safety and tolerability of RD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: MBG453 + NIS793 combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with combination of MBG453 and NIS793 Q3W to confirm safety and tolerability of combination RD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5: MBG453 + canakinumab combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with MBG453 + canakinumab combination Q4W to confirm safety and tolerability of combination RD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBG453</intervention_name>
    <description>Anti-TIM3 monoclonal antibody</description>
    <arm_group_label>Arm 1: MBG453 single agent</arm_group_label>
    <arm_group_label>Arm 4: MBG453 + NIS793 combination</arm_group_label>
    <arm_group_label>Arm 5: MBG453 + canakinumab combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NIS793</intervention_name>
    <description>Anti-TGF-β monoclonal antibody</description>
    <arm_group_label>Arm 2: NIS793 single agent</arm_group_label>
    <arm_group_label>Arm 4: MBG453 + NIS793 combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>canakinumab</intervention_name>
    <description>Anti-IL-1β monoclonal antibody</description>
    <arm_group_label>Arm 3: canakinumab single agent</arm_group_label>
    <arm_group_label>Arm 5: MBG453 + canakinumab combination</arm_group_label>
    <other_name>ACZ885</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent must be obtained prior to participation in the study.&#xD;
&#xD;
          2. Patients must be ≥ 18 years of age at the time of signing the informed consent form&#xD;
             (ICF).&#xD;
&#xD;
          3. Patients must have a diagnosis prior to participation in the study of IPSS-R very low,&#xD;
             low, or intermediate risk MDS with ≤10% bone marrow blasts and one or more of the&#xD;
             following:&#xD;
&#xD;
               1. Symptomatic anemia with hemoglobin &lt;10 g/dL that has relapsed after or is&#xD;
                  refractory to ESAs (or the patient is intolerant to ESAs)&#xD;
&#xD;
               2. Symptomatic anemia with hemoglobin &lt;10 g/dL) that is ESA-naive with EPO level ≥&#xD;
                  500 /uL&#xD;
&#xD;
               3. Thrombocytopenia with platelets &lt;30,000/uL or with clinically significant&#xD;
                  bleeding or bruising and platelets &lt;50,000/uL&#xD;
&#xD;
               4. Neutropenia with an absolute neutrophil count (ANC) &lt;500/ µL or with recurrent&#xD;
                  and/or severe infections and an ANC that is &lt;1000/ µL and amenable to response&#xD;
                  assessments by International Working Group (IWG) response criteria in&#xD;
                  myelodysplasia (Cheson et al 2006)&#xD;
&#xD;
          4. Patients who are refractory to, intolerant of, or ineligible/unable to receive SOC&#xD;
             therapeutic options including lenalidomide&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2&#xD;
&#xD;
          6. Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to&#xD;
             the institutions' guidelines and be willing to undergo a bone marrow aspirate and/or&#xD;
             biopsy at screening, during and at the end of therapy on this study -&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Systemic antineoplastic therapy (including cytotoxic chemotherapy, alpha-interferon,&#xD;
             kinase inhibitors or other targeted small molecules, and toxin-immunoconjugates) or&#xD;
             any experimental therapy within 14 days or 5 half-lives, whichever is longer, before&#xD;
             the first dose of study treatment.&#xD;
&#xD;
          2. History of hypersensitivity to any of the study treatments or its excipients or to&#xD;
             drugs of similar chemical classes.&#xD;
&#xD;
          3. Patients with chronic myelomonocytic leukemia (CMML) or&#xD;
             myelodysplastic/myeloproliferative neoplasms (MDS/MPN)&#xD;
&#xD;
          4. Use of hematopoietic colony-stimulating growth factors (e.g. G-CSF, GM-CSF, M-CSF),&#xD;
             thrombopoietin mimetics or ESAs anytime ≤ 2 weeks (or 5 half-lives, whichever is&#xD;
             longer) prior to start of study treatment.&#xD;
&#xD;
          5. Systemic chronic corticosteroid therapy (&gt;10 mg/day prednisone or equivalent) or any&#xD;
             immunosuppressive therapy within 7 days of first dose of study treatment. Topical,&#xD;
             inhaled, nasal and ophthalmic steroids are allowed.&#xD;
&#xD;
          6. For arms containing canakinumab: Patients with ANC &lt; 500 /µL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MD Anderson Cancer Center/University of Texas MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bailey Mirabella</last_name>
      <phone>713-792-7305</phone>
      <email>BLMirabella@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Guillermo Garcia-Manero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla Y Leon</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic</keyword>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

